Please provide your email address to receive an email when new articles are posted on . The study included 72 individuals with ischemic stroke given alteplase and tenecteplase. No significant time ...

Recent research has revealed compelling evidence supporting tenecteplase as a more effective treatment for ischemic strokes compared to traditional alteplase therapy. This discovery could mark a major ...

Tenecteplase given 4.5-24 hours post-stroke does not boost functional outcomes in patients with occlusions of the internal carotid artery or M1 or M2 segments of the middle cerebral artery who showed ...

Japanese trial compared lytics for bridging before endovascular thrombectomy ...

Making the switch from alteplase to tenecteplase for stroke thrombolysis can be done successfully when the appropriate preparations are taken, and it may improve patient outcomes, the experience of a ...

Please provide your email address to receive an email when new articles are posted on . The findings were presented in a poster at the American College of Allergy, Asthma & Immunology Annual ...

SOUTH SAN FRANCISCO, Calif., March 03, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has ...

Whether the evidence supports wider use of tenecteplase (TNKase; Genentech)—a thrombolytic agent with an indication for acute MI—as an alternative to alteplase (Activase; Genentech) for the treatment ...

Patients with an ischemic stroke treated with tenecteplase have almost a 50% lower rate of symptomatic intracranial hemorrhage (sICH) compared with those receiving alteplase, preliminary results from ...